BACKGROUND/AIM: Japanese Gastric Cancer Treatment Guidelines do not recommend adjuvant chemotherapy after radical gastrectomy for pathological stage (p) T1N+ or pT2~3N0 gastric cancer. However, some patients experience disease recurrence. This study aimed to identify the risk factors for recurrence in pT1N+ or pT2-3N0 gastric cancer. PATIENTS AND METHODS: The study included 157 patients with diagnosed pT1N+ or pT2-3N0 gastric cancer who underwent radical gastrectomy at our institution between January 2001 and December 2020. Clinicopathological data and surgical data were obtained. Independent prognostic factors were analyzed using a Cox proportional hazards regression model. RESULTS: Thirteen patients (8.3%) experienced disease recurrence. Multivariate analysis revealed that the number of examined lymph nodes was an independent prognostic factor for recurrence-free survival (hazard ratio=10.90; 95% confidence interval=1.39-85.86; p=0.023). The group with ≤35 examined lymph nodes had significantly worse recurrence-free survival compared with the group with ≥36 examined lymph nodes (80.7% versus 98.7%; p=0.0005). CONCLUSION: The number of examined lymph nodes (≤35) was an independent risk factor for recurrence after radical gastrectomy with pT1N+ or pT2-3N0 gastric cancer. Copyright 2022, International Institute of Anticancer Research.
BACKGROUND/AIM: Japanese Gastric Cancer Treatment Guidelines do not recommend adjuvant chemotherapy after radical gastrectomy for pathological stage (p) T1N+ or pT2~3N0 gastric cancer. However, some patients experience disease recurrence. This study aimed to identify the risk factors for recurrence in pT1N+ or pT2-3N0 gastric cancer. PATIENTS AND METHODS: The study included 157 patients with diagnosed pT1N+ or pT2-3N0 gastric cancer who underwent radical gastrectomy at our institution between January 2001 and December 2020. Clinicopathological data and surgical data were obtained. Independent prognostic factors were analyzed using a Cox proportional hazards regression model. RESULTS: Thirteen patients (8.3%) experienced disease recurrence. Multivariate analysis revealed that the number of examined lymph nodes was an independent prognostic factor for recurrence-free survival (hazard ratio=10.90; 95% confidence interval=1.39-85.86; p=0.023). The group with ≤35 examined lymph nodes had significantly worse recurrence-free survival compared with the group with ≥36 examined lymph nodes (80.7% versus 98.7%; p=0.0005). CONCLUSION: The number of examined lymph nodes (≤35) was an independent risk factor for recurrence after radical gastrectomy with pT1N+ or pT2-3N0 gastric cancer. Copyright 2022, International Institute of Anticancer Research.
Authors: Paolo Aurello; Francesco D'Angelo; Simone Rossi; Riccardo Bellagamba; Claudia Cicchini; Giuseppe Nigri; Giorgio Ercolani; Renato De Angelis; Giovanni Ramacciato Journal: Am Surg Date: 2007-04 Impact factor: 0.688
Authors: Jaffer A Ajani; Thomas A D'Amico; David J Bentrem; Joseph Chao; David Cooke; Carlos Corvera; Prajnan Das; Peter C Enzinger; Thomas Enzler; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael K Gibson; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Sunnie Kim; Lawrence R Kleinberg; Samuel J Klempner; Jill Lacy; Quan P Ly; Kristina A Matkowskyj; Michael McNamara; Mary F Mulcahy; Darryl Outlaw; Haeseong Park; Kyle A Perry; Jose Pimiento; George A Poultsides; Scott Reznik; Robert E Roses; Vivian E Strong; Stacey Su; Hanlin L Wang; Georgia Wiesner; Christopher G Willett; Danny Yakoub; Harry Yoon; Nicole McMillian; Lenora A Pluchino Journal: J Natl Compr Canc Netw Date: 2022-02 Impact factor: 11.908
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702